TAD after NAC for node-positive breast cancer

Phase 2

Recruiting

• Conditions: node-positive primary breast cancer at dianosis who receive neoadjuvant chemotherapy; Breast Neoplasm; D001943

• Registration Number: JPRN-jRCT1032210236
• Lead Sponsor: Hayashi Naoki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

1. Estrogen receptor negative invasive ductal carcinoma
2. Axillary lymphnode metastasis confirmed by biopsy or cytology at diagnosis
3. Upto 3 axillary lymphnode metastases on ultrasound or CT at diagnosis
4. A clinical T1 or T2 invasive ductal carcinoma
5. Candidate for anthracycline and taxane-based neoadjuvant chemotherapy
6. 20 year or older
7. Written patient Informed consent
8. Performance status: ECOG 0 -1
9. Maintained organ function

Exclusion Criteria

1. Stage IV disease with distant metastasis
2. Pregnancy
3. Inflammatory breast cancer
4. Invasive lobular or invasive micropapillary carcinoma
5.bilateral breast cancer
6. Metal allergy
7. Prior history of axillary surgery or radiation therapy on axillary field
8. Active infection disease
9. Inability to join the study due to mental status
10. BMI: Body mass index 35 or higher
11. Other conditions regarded as intoleratable for the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified